About Moberg Pharma
Moberg Pharma is a publicly listed company based in Bromma (Sweden) founded in 2006. OTC and generic dermatological products are developed and marketed. Moberg Pharma has raised $16.87 million across 7 funding rounds from investors including Bure Equity, Eurostars and Östersjöstiftelsen. Moberg Pharma has completed 5 acquisitions, including Alternallc.com, Dermoplast and Fiber Choice. Its chief executive, as recorded, is Anna Ljung. Moberg Pharma offers products and services including MOB-015 and Terclara. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Moberg Pharma AB (publ).
Company details
Moberg Pharma was founded in 2006 in Bromma, Sweden, within the pharmaceutical sector. OTC and generic products are focused on, with an initial emphasis on dermatology that has since expanded. Treatments for fungal nail infections, psoriasis, cracked heels via foot ointments, diaper rash, and general skin irritation are provided. Operations center on product development and distribution in these areas.
- Headquarters Bromma, Sweden
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mobergpharma.com
- Social LinkedIn X
- Legal Name Moberg Pharma Ab (Publ)
- Total Equity Funding$16.87M (USD)
in 7 rounds
- Latest Funding Round$10M (USD), Debt – Conventional
Jun 2016
- InvestorsBure Equity
& 2 more
- Investments & AcquisitionsAlternallc.com
& 4 more
Products & Services of Moberg Pharma
Moberg Pharma offers a comprehensive portfolio of products and services, including MOB-015 and Terclara.
This product is developed as a treatment for nail fungus and is marketed in various EU countries
This medicine is offered as a solution for mild to moderate nail fungus on fingers and toes, with usage guidelines specified for adults
Funding Insights of Moberg Pharma
Moberg Pharma has successfully raised a total of $16.87M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.87M
- Total Rounds 7
- Last Round Debt – Conventional — $10M
- First Round $4.03M
(Jun 2007)
- Investors Count 3
All 7 funding rounds of Moberg Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $10M | Debt – Conventional | – | – | – |
| Jun 2015 | $1.01M | Grant | – | – | |
| Jul 2013 | $5.38M | Post-IPO | – | – | |
| Dec 2009 | $1.37M | Series B | – | – | – |
| Aug 2009 | $4.97M | Series B | – | – | – |
| Mar 2008 | $6.5M | Series B | – | – | |
| Jun 2007 | $4.03M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Moberg Pharma
Moberg Pharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Bure Equity, Eurostars and Östersjöstiftelsen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on science, manufacturing, healthcare, and multiple sectors | 1992 | bure.se | Stockholm, Sweden | |
Research funding is provided for Baltic and Eastern European studies. | ostersjostiftelsen.se | Stockholm, Sweden | ||
| eurostars-eureka.eu |
Investor details for Moberg Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Moberg Pharma
8 people are tracked at Moberg Pharma (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Anna Ljung | CEO | Leadership |
Anders Bröijersén | Chief Medical Officer | Leadership |
Gunilla Wengström | Sales Director | Leadership |
Amir Tavakkol | Chief Scientific Officer | Leadership |
Cindy Wong | Chief Medical Officer /Senior Consultant | Leadership |
Åsa Waltermo | Senior Pharmaceutical Manager | Team |
Cecilia Ström | Clinical Program Leader | Team |
Ewa Karlsson | Formulation Manager | Team |
Complete people profiles for Moberg Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Moberg Pharma
Moberg Pharma has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Alternallc.com, Dermoplast and Fiber Choice.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
First aid and pain treatment sprays are manufactured by Dermoplast. | dermoplast.com | Hanover, United States | 2000 | Dec 2016 | $47.6M | |
Cold and flu relief medicines are manufactured by Pediacare. | pediacare.com | Buffalo, United States | 1996 | Jul 2016 | •••• | |
Over-the-counter liquid bandages for wound healing are developed. | newskinproducts.com | Hanover, United States | 2000 | Jun 2016 | •••• | |
Fiber supplements for digestive and bone health | fiberchoice.com | Boca Raton, United States | 1998 | Jun 2016 | •••• | |
Limited information is available on core activities. | alternallc.com | Hanover, United States | 2004 | Oct 2012 | $24.82M |
Complete acquisition details for Moberg Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Moberg Pharma
9 dated milestones of Moberg Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Moberg Pharma is founded.
- Funding First funding round of $4.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Alternallc.com.
- Funding Latest funding round, Debt – Conventional, of $10.0M.
- Acquisition Acquires Fiber Choice.
- Acquisition Acquires New Skin.
- Acquisition Acquires Pediacare.
- Acquisition Acquires Dermoplast.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Moberg Pharma
Complete news archive for Moberg Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Moberg Pharma
Moberg Pharma was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Moberg Pharma is headquartered in Bromma, Sweden. It is registered at Bromma, Stockholms Lan, Sweden.
Anna Ljung is the CEO of Moberg Pharma, as recorded in our data.
Moberg Pharma is a funded company, having raised a total of $16.87M across 7 funding rounds to date. The company's 1st funding round was a Series A of $4.03M, raised on Jun 2007.
Moberg Pharma was founded in 2006 in Bromma, Sweden, within the pharmaceutical sector. OTC and generic products are focused on, with an initial emphasis on dermatology that has since expanded. Treatments for fungal nail infections, psoriasis, cracked heels via foot ointments, diaper rash, and general skin irritation are provided. Operations center on product development and distribution in these areas.
Moberg Pharma offers MOB-015 and Terclara.
Moberg Pharma has made 5 acquisitions, including Alternallc.com, Dermoplast, and Fiber Choice.
Moberg Pharma has 3 investors. Key investors include Bure Equity, Eurostars, and Östersjöstiftelsen.
Moberg Pharma operates through Moberg Pharma Ab (Publ).